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are found with SEPS. Do you have a technique to identify those
perforators? Will you perform SEPS, if you have a recurrent ulcer,
after the perforators have been sclerosed?
Dr Masuda. The solution we used was a liquid sclerosant,
sodium morrhuate. At our institution, that is the only FDA-
approved solution we are allowed to use. We use the full-strength
5% solution and 1.5 cc is injected into each perforator vein. It is
imperative to aspirate first, and then inject the perforator under
duplex imaging. If there is any resistance, we stop injecting.
It is quite surprising that DVT of the calf veins are rare. We
routinely compress the limb after UGS with an elastic wrap padded
with cotton to prevent some of that deep venous stasis that might
occur after injections.
As far as other perforators, the paratibial perforators were only
treated if they were of substantial size. Perforator veins less than 2
mm were not treated. As you pointed out, there were likely some
paratibial veins not seen by duplex.
Dr Peter Gloviczki (Rochester, Minn). I’d like to echo what
Mr Burnand said, that it is extremely rare to have an isolated
perforator vein incompetence, 5% or less in our experience. So I’m
wondering what predicted recurrence of perforators in your study?
Was it popliteal reflux or maybe superficial reflux? Did you find any
correlation of recurrent perforators and some other pathology or
maybe post-thrombotic syndrome?
And then just a final comment that the new terminology for the
saphenous vein is great saphenous vein. And the way to remember it,
for everybody, is that it’s Great Britain, it’s not Long Britain.
Dr Masuda. When we studied the variables that may have
explained ulcer recurrence, we did not find a correlation between
deep and superficial reflux and ulcer recurrence in those with
concomitant reflux. It may have been that our study group was just
a little too small to show that, but we did find that post-thrombotic
disease was related to ulcer recurrence.
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All physicians with patients suffering from venous disease
continue to search for effective treatment methods, particularly for
patients with the most severe complication of the disease—chronic
ulceration.Masuda et al have described the use of ultrasound-guided
sclerotherapy (UGS) of incompetent perforator veins in 80 limbs of
68 patients. Venous clinical severity and disability scores were both
improved. Most importantly, 32 of 37 ulcers were healed, although a
minority required more than one treatment. The authors stated that
even patients treated for swelling only were significantly improved.
The authors offer two caveats: this therapy should not be applied in
patients with lymphedema, and skin necrosis may occur if the sclero-
sant is injected in an adjacent artery. In summary, this report adds
additional information that suggests UGS may be helpful in these
patients with recalcitrant venous problems.
The authors also describe their techniquewell enough so that any
physician familiar with sclerotherapy and noninvasive vascular labora-
tory technology would likely feel competent to attempt UGS.
The issue in this paper that is less clear is that of patient
selection. “Most” of the patients had no “axial” reflux, only
perforator incompetence. The number of these patients in the
series is never identified. How do patients with no “axial” venous
valvular incompetence of the saphenous or deep venous systems
develop severe lipodermatosclerosis and ulceration? Is the evalua-
tion of venous valve function accurate? The authors’ method seems
to meet the standard of most vascular labs. Because the mechanism
of disease in patients with only perforator incompetence is unclear,
application of this treatment to such patients would seem less likely
to succeed, although the risks would be few and ulcer healing, if
achieved, a great boon.
This does appear to be a promising technique for those
patients with severe complications of venous valvular dysfunction
whose saphenous system is competent or removed and whose
valvular function in the deep system and perforators is compro-
mised.
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